Seaport Therapeutics posts second-quarter loss as GlyphAllo and GlyphAgo advance
The Boston clinical-stage company said its lead neuropsychiatric programs remain on schedule after a May IPO raised $260.0 million and lifted cash to $427.3 million at June 30.